Search Results 941-950 of 16369 for monoclonal antibody
Rajkumar said multiple myeloma is always preceded sequentially by two asymptomatic conditions, monoclonal gammopathy of undetermined significance (MGUS) and ...
Prior monoclonal antibody within 4 weeks prior to study Day 1 (2 weeks for RS participants) or who has not recovered (i.e. ≤ Grade 1 or at baseline) from ...
... monoclonal antibodies, and not a candidate for ... antibody syndrome. Patients receiving dual ... antibody positive, confirmed by HCV ribonucleic acid).
... antibody at any point prior to registration -CD20-targeted monoclonal antibody (e.g., rituximab, obinutuzumab or biosimilars) =< 4 weeks prior to ...
Monoclonal antibodies: at least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody; Radiation therapy (RT): >= 2 weeks ...
- The participant has been treated with an anti-?-synuclein monoclonal antibody, mesenchymal stem cells or an inhibitor of ?-synuclein aggregation within ...
... monoclonal antibodies, other investigational agent) < 28 days prior to the first dose of study drug. Current or prior use of immunosuppressive medication ...
At least 28 days since last dose of chemotherapy prior to registration. Monoclonal antibody(ies). At least 28 days since last dose of monoclonal antibody prior ...
Prior immunotherapy & monoclonal antibody therapy are acceptable. Subjects who received prior cytotoxic chemotherapy after incomplete resection of ...
... antibody (including ipilimumab, tremelimumab or any other antibody, or drug specifically targeting T cell co stimulatory or immune checkpoint pathways).
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.